ClinicalTrials.gg
CompletedNCT01543958Updated Oct 11, 2018Results posted

Sevelamer for Reducing Endotoxemia and Immune Activation

A Phase 2 interventional study of Sevelamer carbonate and Sevelamer carbonate in HIV-1 Infection, sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-11.

Sponsored by Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

HIV-infected people can have an increase in inflammation in their body organs, even after taking anti-HIV medicines.

Sevelamer carbonate is used to bind phosphate in dialysis patients. It can also bind endotoxin in the gut and lowers endotoxin levels in the blood of dialysis patients. Sevelamer carbonate decreases the inflammation endotoxin causes in dialysis patients.

A5296 is a phase II, single-arm study to evaluate the effect of 8 weeks of sevelamer carbonate administration on markers of microbial translocation and T-cell activation in the blood in chronically HIV-infected subjects not receiving ART.

Read the detailed description

HIV-infected people can have an increase in inflammation in their body organs, even after taking anti-HIV medicines. Inflammation is a normal body reaction to any infection. However, if inflammation lasts a long time like in HIV infection, it may lead to complications, such as heart disease, cancer, liver disease, and problems with thinking. Also, HIV-infected people with high inflammation have lower CD4+ T-cell counts (cells that fight infection). Many HIV researchers are studying the harmful effects of this prolonged inflammation and possible ways to prevent these complications.

The increase in inflammation in HIV-infected people may be caused by HIV or by other factors such as parts of bacteria. These bacterial pieces, called endotoxins, do not cause harm in the intestine (gut). However, in HIV infection, there is damage to the gut that allows endotoxins to cross from the gut into the blood. These endotoxins then cause inflammation in the body. New research is focusing on strategies to reduce the levels of endotoxin as a way to decrease inflammation.

A drug called sevelamer carbonate is used to bind phosphate in dialysis patients. However, sevelamer carbonate also binds endotoxin in the gut and lowers endotoxin levels in the blood of dialysis patients. Sevelamer carbonate also decreases the inflammation endotoxin causes in dialysis patients. This study will see if sevelamer carbonate can have the same effects in HIV-infected patients.

A5296 is a phase II, single-arm study to evaluate the effect of 8 weeks of sevelamer carbonate administration on markers of microbial translocation as well as monocyte and T-cell activation in the blood in chronically HIV-infected subjects with CD4+ T-cell count ≥ 400 cells/mm3 not receiving ART. This study enrolled 40 subjects. To assess whether there is a persistent effect of study drug, subjects were observed for an additional 8 weeks off sevelamer carbonate and changes in biomarkers were monitored.

As A5296 is a phase II study of biologic activity, the primary and secondary analyses are as-treated, limited to subjects who have data for baseline and week 8 and who remain on study treatment through week 8. For any subject who initiated antiretroviral treatment (ART), analyses only included data collected prior to the time ART was started.

02

Conditions studied

  • HIV-1 Infection
03

In context

Lead sponsor

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections is the lead sponsor of 70 studies on the registry; 3 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 6 (86%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -1 infection
  • No plans to initiate ART during the course of the proposed study.
  • Screening ≥ 400 cells/mm3 performed in a laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent.
  • HIV-1 RNA >50 copies/mL within the last 180 days prior to entry.
  • Screening serum phosphate > 2.6 mg/dL within 60 days prior to entry.
  • Certain laboratory values, as detailed in section 4.1.6 of the protocol, obtained within 30 days prior to entry
  • Female subjects of must have a negative serum or urine pregnancy test performed within 30 days prior to entry.
  • Female subjects participating in sexual activity that could lead to pregnancy must agree to use at least one of the following forms of for at least 30 days prior to study entry until the final study visit:

    • Condoms (male or female) with or without a spermicidal agent
    • Diaphragm or cervical cap with spermicide
    • Intrauterine device (IUD)
    • Hormone-based contraceptive
  • Female subjects who are not of reproductive potential are eligible without requiring the use of a contraceptive.
  • Confirmation of the availability of the stored pre-entry plasma and peripheral blood mononuclear cell (PBMC) samples for endotoxin, sCD14, and immune activation determinations, obtained from a fasting sample.
  • Ability and willingness of subject to provide .
  • No plans to use probiotics (defined as products that contain significant amounts of live microorganisms and are ingested for specific health benefits, e.g., yogurt with live and active cultures, Lactobacillus GG, Saccharomyces boulardii) during the study.

Exclusion criteria

Exclusion Criteria:

  • Known diagnosis of acute infection within 180 days prior to study entry.
  • Pregnant or breastfeeding.
  • Use of any antiretroviral agent within 24 weeks prior to study entry.
  • Use of systemic cancer chemotherapy or radiation therapy, or immunomodulatory therapy (e.g., interferons, tumor necrosis factor antagonists, interleukins, systemic ) within 24 weeks prior to study entry.

NOTE A: Use of inhaled steroids, nasal steroids, topical steroids, or the equivalent of 10 mg of prednisone or less per day or a less than 2-week course of oral steroids is not exclusionary.

NOTE B: A single course of 1% hydrocortisone cream applied up to 3 times a day to \<10 square inches area for \<2 weeks is permitted while on study. Use of all other topical steroids is excluded.

  • Known allergy/sensitivity or any to components of the study drug or its formulation.
  • Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
  • Serious illness requiring systemic treatment and/or hospitalization within 60 days prior to study entry.
  • Known cirrhosis or severe liver disease (e.g., ascites, encephalopathy, history of variceal bleeding).

NOTE: Potential subjects with chronic or C virus infection who do not have known cirrhosis or severe liver disease may participate in the study.

  • Severe kidney disease (defined as estimated [GFR] \<30 mL/min/1.73m2) at screening.
  • History of bowel obstruction or severe GI motility disorders including severe constipation.
  • Severe dysphagia or swallowing disorders.
  • Major GI tract surgery within 60 days prior to study entry.
  • Intent to initiate or change the dose of lipid-lowering drugs during study. NOTE: Potential subjects on stable doses of lipid-lowering agents (defined as no change in preparation or dose within 90 days prior to study entry) are permitted and may be enrolled.
  • Use of therapies within 90 days prior to study entry unless permission was granted by the A5296 protocol chairs (see Study Management page).
  • Currently receiving therapy or anticipation that such therapy will be started during the study.
  • Use of probiotics, for more than 3 consecutive days within the 60 days prior to study entry.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Sevelamer carbonate

    Patients will be administered two 800 mg tablets of Sevelamer carbonate orally three times a day for 8 weeks.

    Drug: Sevelamer carbonate · Device: Sevelamer carbonate

Interventions

  • DrugSevelamerStudies of SevelamerSevelamer pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will be administered two 800 mg tablets of Sevelamer carbonate orally three times a day for 8 weeks.

    Also known as: Renvela

  • DeviceSevelamer carbonate

    Also known as: Renvela

06

What researchers measure

Primary outcomes

  1. Change in Endotoxin

    Change in LPS from baseline to week 8, where baseline value is the average of pre-entry and entry values.

    Time frame: baseline and Week 8

  2. Change in Soluble CD14 (sCD14)

    Change in soluble CD14 (sCD14) from baseline to week 8, where baseline value is the average of pre-entry and entry

    Time frame: baseline and week 8

Secondary outcomes

  1. Change in Endotoxin

    Change in endotoxin from baseline to week 4, where baseline value is the average of pre-entry and entry

    Time frame: baseline and week 4

  2. Change in Endotoxin

    Change in endotoxin from week 8 to week 16

    Time frame: week 8 and week 16

  3. Change in sCD14

    Change in sCD14 from baseline to week 4, where baseline value is the average of pre-entry and entry

    Time frame: baseline and week 4

  4. Change in sCD14

    Change in sCD14 from week 8 to week 16

    Time frame: week 8 and week 16

  5. Change in CD4+ T-cell Activation

    Change from baseline to week 8 in CD4+ T-cell activation, defined as the %CD38+/HLA-DR+, where baseline value is the average of pre-entry and entry

    Time frame: baseline and week 8

  6. Change in CD4+ T-cell Activation

    Change from baseline to week 4 in CD4+ T-cell activation, defined as the %CD38+/HLA-DR+, where baseline value is the average of pre-entry and entry

    Time frame: baseline and week 4

  7. Change in CD4+ T-cell Activation

    Change from week 8 to week 16 in CD4+ T-cell activation, defined as the %CD38+/HLA-DR+

    Time frame: week 8 and week 16

  8. Change in CD8+ T-cell Activation

    Change from baseline to week 4 in CD8+ T-cell activation, defined as the %CD38+/HLA-DR+, where baseline value is the average of pre-entry and entry

    Time frame: baseline and week 4

  9. Change in CD8+ T-cell Activation

    Change in CD8+ T-cell activation defined as the %CD38+/HLA-DR+ from baseline to week 8, where baseline is the average of pre-entry and entry

    Time frame: Baseline and Week 8

  10. Change in CD8+ T-cell Activation

    Change in CD8+ T-cell activation defined as the %CD38+/HLA-DR+ from week 8 to week 16

    Time frame: week 8 and week 16

  11. Change in Proportion of Cycling CD8+

    Change from baseline to week 4 in cycling CD8+ , defined as the %Ki67+, where baseline value is the average of pre-entry and entry

    Time frame: baseline and week 4

  12. Change in Proportion of Cycling CD8+

    Change from baseline to week 8 in cycling CD8+ , defined as the %Ki67+, where baseline value is the average of pre-entry and entry

    Time frame: baseline and week 8

  13. Change in Proportion of Cycling CD8+

    Change from week 8 to week 16 in cycling CD8+ , defined as the %Ki67+

    Time frame: from week 8 to week 16

  14. Change in Proportion of Cycling CD4+

    Change from baseline to week 4 in cycling CD4+ , defined as the %Ki67+, where baseline value is the average of pre-entry and entry

    Time frame: baseline and week 4

  15. Change in Proportion of Cycling CD4+

    Change from baseline to week 8 in cycling CD4+ , defined as the %Ki67+, where baseline value is the average of pre-entry and entry

    Time frame: baseline and week 8

  16. Change in Proportion of Cycling CD4+

    Change from week 8 to week 16 in cycling CD4+ , defined as the %Ki67+

    Time frame: week 8 and week 16

  17. Change in Blood Phosphate Levels

    Change in blood phosphate levels from baseline to week 4, where baseline value is the average of pre-entry and entry

    Time frame: from baseline to week 4

  18. Change in Blood Phosphate Levels

    Change in blood phosphate levels from baseline to week 8

    Time frame: Baseline to Week 8

  19. Change in Blood Phosphate Levels

    Change in blood phosphate levels from week 8 to week 16

    Time frame: from week 8 to week 16

  20. Change in log10 HIV RNA Levels

    Change in log10 HIV RNA levels from baseline to week 4, where baseline value is the average of pre-entry and entry

    Time frame: baseline and week 4

  21. Change in log10 HIV RNA Levels

    Change in log10 HIV RNA levels from baseline to week 8, where baseline value is the average of pre-entry and entry

    Time frame: baseline and week 8

  22. Change in log10 HIV RNA Levels

    Change in log10 HIV RNA levels from week 8 to week 16

    Time frame: week 8 and week 16

  23. Change in CD4+ T-cell Counts

    Change in CD4+ T-cell counts from baseline to week 4, where baseline is the average of pre-entry and entry

    Time frame: baseline and week 4

  24. Change in CD4+ T-cell Counts

    Change in CD4+ T-cell counts from baseline to week 8, where baseline is the average of pre-entry and entry

    Time frame: baseline and week 8

  25. Change in CD4+ T-cell Counts

    Change in CD4+ T-cell counts from week 8 to week 16

    Time frame: week 8 and week 16

  26. Change in IL-6

    Changes in levels of systemic inflammation marker IL-6 from baseline to week 4, where baseline is the average of pre-entry and entry

    Time frame: baseline and week 4

  27. Change in IL-6

    Changes in levels of systemic inflammation marker IL-6 from baseline to week 8, where baseline is the average of pre-entry and entry

    Time frame: baseline and week 8

  28. Change in IL-6

    Changes in levels of systemic inflammation marker IL-6 from week 8 to week 16

    Time frame: week 8 and week 16

  29. Change in C-reactive Protein (CRP)

    Changes in levels of systemic inflammation marker CRP from baseline to week 4, where baseline is the average of pre-entry and entry

    Time frame: baseline and week 4

  30. Change in CRP

    Changes in levels of systemic inflammation marker CRP from baseline to week 8, where baseline is the average of pre-entry and entry

    Time frame: Baseline and Week 8

  31. Change in CRP

    Changes in levels of systemic inflammation marker CRP from week 8 to week 16, where baseline is the average of pre-entry and entry

    Time frame: week 8 and week 16

  32. Change in D-dimer

    Change in levels of coagulation biomarker d-dimer from baseline to week 4, where baseline value is the average of pre-entry and entry

    Time frame: baseline and week 4

  33. Change in D-dimer

    Change in levels of coagulation biomarker d-dimer from baseline to week 8, where baseline value is the average of pre-entry and entry

    Time frame: baseline and week 8

  34. Change in D-dimer

    Change in levels of coagulation biomarker d-dimer from week 8 to week 16

    Time frame: week 8 and week 16

  35. Change in Tissue Factor

    Change in levels of coagulation biomarker tissue factor from baseline to week 4, where baseline value is the average of pre-entry and entry

    Time frame: baseline and week 4

  36. Change in Tissue Factor

    Change in levels of coagulation biomarker tissue factor from baseline to week 8, where baseline value is the average of pre-entry and entry

    Time frame: baseline and week 8

  37. Change in Tissue Factor

    Change in levels of coagulation biomarker tissue factor from week 8 to week 16

    Time frame: week 8 and week 16

  38. Change in Total Cholesterol

    Change in total cholesterol from baseline to week 8, where baseline value is the average of pre-entry and entry

    Time frame: baseline and week 8

  39. Change in Total Cholesterol

    Change in total cholesterol from week 8 to week 16

    Time frame: week 8 and week 16

  40. Change in LDL Cholesterol

    Change in fasting LDL cholesterol from baseline to week 8, where baseline value is the average of pre-entry and entry

    Time frame: baseline and week 8

  41. Change in LDL Cholesterol

    Change in fasting LDL cholesterol from week 8 to week 16

    Time frame: week 8 and week 16

  42. Change in HDL Cholesterol

    Change in fasting HDL cholesterol from baseline to week 8, where baseline value is the average of pre-entry and entry

    Time frame: baseline and week 8

  43. Change in HDL Cholesterol

    Change in fasting HDL cholesterol from week 8 to week 16

    Time frame: from week 8 to week 16

  44. Change in Non-HDL Cholesterol

    Change in non-HDL cholesterol from baseline to week 8, where baseline value is the average of pre-entry and entry

    Time frame: baseline and week 8

  45. Change in Non-HDL Cholesterol

    Change in non-HDL cholesterol from week 8 to week 16

    Time frame: week 8 and week 16

  46. Change in Fasting Glucose

    Change in fasting glucose from baseline to week 8, where baseline value is the average of pre-entry and entry

    Time frame: baseline and week 8

  47. Change in Fasting Glucose

    Change in fasting glucose from week 8 to week 16

    Time frame: week 8 and week 16

  48. Primary Adverse Events

    Number of subjects experiencing primary adverse events, defined as all reported Grade ≥ 2 signs and symptoms, Grade ≥ 2 laboratory abnormalities and other serious adverse events (SAEs)

    Time frame: baseline and week 16

07

Results

Posted Nov 25, 2013

Participant flow

A5296 accrual opened under protocol version 1.0 on 11/21/11, and the first subject was enrolled on 12/29/11. Accrual to the study closed on 8/1/12, with a total of 40 subjects enrolled from 15 sites within the US.

Participant flow — Overall Study
MilestoneSevelamer Carbonate
Started40
Completed36
Not completed4
Withdrew: Loss to follow-up3
Withdrew: Art initiation1

Outcome measures

PrimaryChange in Endotoxin

Change in LPS from baseline to week 8, where baseline value is the average of pre-entry and entry values.

Time frame:
baseline and Week 8
Reported as:
Median · pg/mL
Change in Endotoxin
pg/mLSevelamer Carbonate
Change in Endotoxin0.20 (-4.06 to 5.81)
Statistical analysis
  • Sevelamer Carbonate · Sign test · p = 0.87 (not adjusted for multiple comparisons)no other adjustment
PrimaryChange in Soluble CD14 (sCD14)

Change in soluble CD14 (sCD14) from baseline to week 8, where baseline value is the average of pre-entry and entry

Time frame:
baseline and week 8
Reported as:
Median · ug/mL
Change in Soluble CD14 (sCD14)
ug/mLSevelamer Carbonate
Change in Soluble CD14 (sCD14)-0.02 (-0.18 to 0.06)
Statistical analysis
  • Sevelamer Carbonate · Sign test · p = 0.62 (Not adjusted for multiple comparisons)no other adjustment
SecondaryChange in Endotoxin

Change in endotoxin from baseline to week 4, where baseline value is the average of pre-entry and entry

Time frame:
baseline and week 4
Reported as:
Median · pg/mL
Change in Endotoxin
pg/mLSevelamer Carbonate
Change in Endotoxin1.08 (-2.51 to 7.71)
SecondaryChange in Endotoxin

Change in endotoxin from week 8 to week 16

Time frame:
week 8 and week 16
Reported as:
Median · pg/mL
Change in Endotoxin
pg/mLSevelamer Carbonate
Change in Endotoxin-2.39 (-8.04 to 2.65)
SecondaryChange in sCD14

Change in sCD14 from baseline to week 4, where baseline value is the average of pre-entry and entry

Time frame:
baseline and week 4
Reported as:
Median · ug/mL
Change in sCD14
ug/mLSevelamer Carbonate
Change in sCD14-0.09 (-0.23 to 0.11)
SecondaryChange in sCD14

Change in sCD14 from week 8 to week 16

Time frame:
week 8 and week 16
Reported as:
Median · ug/mL
Change in sCD14
ug/mLSevelamer Carbonate
Change in sCD140.06 (-0.03 to 0.24)
SecondaryChange in CD4+ T-cell Activation

Change from baseline to week 8 in CD4+ T-cell activation, defined as the %CD38+/HLA-DR+, where baseline value is the average of pre-entry and entry

Time frame:
baseline and week 8
Reported as:
Median · percentage
Change in CD4+ T-cell Activation
percentageSevelamer Carbonate
Change in CD4+ T-cell Activation0.050 (-0.650 to 2.600)
SecondaryChange in CD4+ T-cell Activation

Change from baseline to week 4 in CD4+ T-cell activation, defined as the %CD38+/HLA-DR+, where baseline value is the average of pre-entry and entry

Time frame:
baseline and week 4
Reported as:
Median · percentage
Change in CD4+ T-cell Activation
percentageSevelamer Carbonate
Change in CD4+ T-cell Activation0.4 (-0.95 to 1.2)
SecondaryChange in CD4+ T-cell Activation

Change from week 8 to week 16 in CD4+ T-cell activation, defined as the %CD38+/HLA-DR+

Time frame:
week 8 and week 16
Reported as:
Median · percentage
Change in CD4+ T-cell Activation
percentageSevelamer Carbonate
Change in CD4+ T-cell Activation0.45 (-0.80 to 1.60)
SecondaryChange in CD8+ T-cell Activation

Change from baseline to week 4 in CD8+ T-cell activation, defined as the %CD38+/HLA-DR+, where baseline value is the average of pre-entry and entry

Time frame:
baseline and week 4
Reported as:
Median · percentage
Change in CD8+ T-cell Activation
percentageSevelamer Carbonate
Change in CD8+ T-cell Activation-0.05 (-4.35 to 3.15)
SecondaryChange in CD8+ T-cell Activation

Change in CD8+ T-cell activation defined as the %CD38+/HLA-DR+ from baseline to week 8, where baseline is the average of pre-entry and entry

Time frame:
Baseline and Week 8
Reported as:
Median · percentage
Change in CD8+ T-cell Activation
percentageSevelamer Carbonate
Change in CD8+ T-cell Activation-0.450 (-1.75 to 1.95)
SecondaryChange in CD8+ T-cell Activation

Change in CD8+ T-cell activation defined as the %CD38+/HLA-DR+ from week 8 to week 16

Time frame:
week 8 and week 16
Reported as:
Median · percentage
Change in CD8+ T-cell Activation
percentageSevelamer Carbonate
Change in CD8+ T-cell Activation-0.15 (-1.9 to 6)
SecondaryChange in Proportion of Cycling CD8+

Change from baseline to week 4 in cycling CD8+ , defined as the %Ki67+, where baseline value is the average of pre-entry and entry

Time frame:
baseline and week 4
Reported as:
Median · percentage
Change in Proportion of Cycling CD8+
percentageSevelamer Carbonate
Change in Proportion of Cycling CD8+-0.125 (-0.55 to 0.275)
SecondaryChange in Proportion of Cycling CD8+

Change from baseline to week 8 in cycling CD8+ , defined as the %Ki67+, where baseline value is the average of pre-entry and entry

Time frame:
baseline and week 8
Reported as:
Median · percentage
Change in Proportion of Cycling CD8+
percentageSevelamer Carbonate
Change in Proportion of Cycling CD8+0.1 (-0.425 to 0.775)
SecondaryChange in Proportion of Cycling CD8+

Change from week 8 to week 16 in cycling CD8+ , defined as the %Ki67+

Time frame:
from week 8 to week 16
Reported as:
Median · percentage
Change in Proportion of Cycling CD8+
percentageSevelamer Carbonate
Change in Proportion of Cycling CD8+0.300 (-0.5 to 0.9)
SecondaryChange in Proportion of Cycling CD4+

Change from baseline to week 4 in cycling CD4+ , defined as the %Ki67+, where baseline value is the average of pre-entry and entry

Time frame:
baseline and week 4
Reported as:
Median · percentage
Change in Proportion of Cycling CD4+
percentageSevelamer Carbonate
Change in Proportion of Cycling CD4+0.125 (-0.375 to 0.575)
SecondaryChange in Proportion of Cycling CD4+

Change from baseline to week 8 in cycling CD4+ , defined as the %Ki67+, where baseline value is the average of pre-entry and entry

Time frame:
baseline and week 8
Reported as:
Median · percentage
Change in Proportion of Cycling CD4+
percentageSevelamer Carbonate
Change in Proportion of Cycling CD4+0.025 (-0.575 to 0.40)
SecondaryChange in Proportion of Cycling CD4+

Change from week 8 to week 16 in cycling CD4+ , defined as the %Ki67+

Time frame:
week 8 and week 16
Reported as:
Median · percentage
Change in Proportion of Cycling CD4+
percentageSevelamer Carbonate
Change in Proportion of Cycling CD4+0.2 (-0.3 to 0.8)
SecondaryChange in Blood Phosphate Levels

Change in blood phosphate levels from baseline to week 4, where baseline value is the average of pre-entry and entry

Time frame:
from baseline to week 4
Reported as:
Median · mg/dL
Change in Blood Phosphate Levels
mg/dLSevelamer Carbonate
Change in Blood Phosphate Levels0 (-0.20 to 0.60)
SecondaryChange in Blood Phosphate Levels

Change in blood phosphate levels from baseline to week 8

Time frame:
Baseline to Week 8
Reported as:
Median · mg/dL
Change in Blood Phosphate Levels
mg/dLSevelamer Carbonate
Change in Blood Phosphate Levels-0.1 (-0.3 to 0.2)
SecondaryChange in Blood Phosphate Levels

Change in blood phosphate levels from week 8 to week 16

Time frame:
from week 8 to week 16
Reported as:
Median · mg/dL
Change in Blood Phosphate Levels
mg/dLSevelamer Carbonate
Change in Blood Phosphate Levels0.10 (-0.30 to 0.40)
SecondaryChange in log10 HIV RNA Levels

Change in log10 HIV RNA levels from baseline to week 4, where baseline value is the average of pre-entry and entry

Time frame:
baseline and week 4
Reported as:
Median · log10(copies/mL)
Change in log10 HIV RNA Levels
log10(copies/mL)Sevelamer Carbonate
Change in log10 HIV RNA Levels0.02 (-0.09 to 0.14)
SecondaryChange in log10 HIV RNA Levels

Change in log10 HIV RNA levels from baseline to week 8, where baseline value is the average of pre-entry and entry

Time frame:
baseline and week 8
Reported as:
Median · log10(copies/mL)
Change in log10 HIV RNA Levels
log10(copies/mL)Sevelamer Carbonate
Change in log10 HIV RNA Levels-0.02 (-0.12 to 0.10)
SecondaryChange in log10 HIV RNA Levels

Change in log10 HIV RNA levels from week 8 to week 16

Time frame:
week 8 and week 16
Reported as:
Median · log10(copies/mL)
Change in log10 HIV RNA Levels
log10(copies/mL)Sevelamer Carbonate
Change in log10 HIV RNA Levels0.16 (-0.11 to 0.31)
SecondaryChange in CD4+ T-cell Counts

Change in CD4+ T-cell counts from baseline to week 4, where baseline is the average of pre-entry and entry

Time frame:
baseline and week 4
Reported as:
Median · cells/mm^3
Change in CD4+ T-cell Counts
cells/mm^3Sevelamer Carbonate
Change in CD4+ T-cell Counts-25 (-86 to 40)
SecondaryChange in CD4+ T-cell Counts

Change in CD4+ T-cell counts from baseline to week 8, where baseline is the average of pre-entry and entry

Time frame:
baseline and week 8
Reported as:
Median · cells/mm^3
Change in CD4+ T-cell Counts
cells/mm^3Sevelamer Carbonate
Change in CD4+ T-cell Counts-14 (-70 to 45)
SecondaryChange in CD4+ T-cell Counts

Change in CD4+ T-cell counts from week 8 to week 16

Time frame:
week 8 and week 16
Reported as:
Median · cells/mm^3
Change in CD4+ T-cell Counts
cells/mm^3Sevelamer Carbonate
Change in CD4+ T-cell Counts-1 (-93 to 69)
SecondaryChange in IL-6

Changes in levels of systemic inflammation marker IL-6 from baseline to week 4, where baseline is the average of pre-entry and entry

Time frame:
baseline and week 4
Reported as:
Median · pg/mL
Change in IL-6
pg/mLSevelamer Carbonate
Change in IL-60.28 (-0.13 to 0.72)
SecondaryChange in IL-6

Changes in levels of systemic inflammation marker IL-6 from baseline to week 8, where baseline is the average of pre-entry and entry

Time frame:
baseline and week 8
Reported as:
Median · pg/mL
Change in IL-6
pg/mLSevelamer Carbonate
Change in IL-6-0.02 (-0.58 to 0.63)
SecondaryChange in IL-6

Changes in levels of systemic inflammation marker IL-6 from week 8 to week 16

Time frame:
week 8 and week 16
Reported as:
Median · pg/mL
Change in IL-6
pg/mLSevelamer Carbonate
Change in IL-60.19 (-0.43 to 1.07)
SecondaryChange in C-reactive Protein (CRP)

Changes in levels of systemic inflammation marker CRP from baseline to week 4, where baseline is the average of pre-entry and entry

Time frame:
baseline and week 4
Reported as:
Median · ng/mL
Change in C-reactive Protein (CRP)
ng/mLSevelamer Carbonate
Change in C-reactive Protein (CRP)-141 (-1283.5 to 845)
SecondaryChange in CRP

Changes in levels of systemic inflammation marker CRP from baseline to week 8, where baseline is the average of pre-entry and entry

Time frame:
Baseline and Week 8
Reported as:
Median · ng/mL
Change in CRP
ng/mLSevelamer Carbonate
Change in CRP45.5 (-652.5 to 1539.5)
SecondaryChange in CRP

Changes in levels of systemic inflammation marker CRP from week 8 to week 16, where baseline is the average of pre-entry and entry

Time frame:
week 8 and week 16
Reported as:
Median · ng/mL
Change in CRP
ng/mLSevelamer Carbonate
Change in CRP-34 (-493 to 527)
SecondaryChange in D-dimer

Change in levels of coagulation biomarker d-dimer from baseline to week 4, where baseline value is the average of pre-entry and entry

Time frame:
baseline and week 4
Reported as:
Median · ng/mL
Change in D-dimer
ng/mLSevelamer Carbonate
Change in D-dimer5.95 (-28.87 to 55.02)
SecondaryChange in D-dimer

Change in levels of coagulation biomarker d-dimer from baseline to week 8, where baseline value is the average of pre-entry and entry

Time frame:
baseline and week 8
Reported as:
Median · ng/mL
Change in D-dimer
ng/mLSevelamer Carbonate
Change in D-dimer20.30 (-16.08 to 74.90)
SecondaryChange in D-dimer

Change in levels of coagulation biomarker d-dimer from week 8 to week 16

Time frame:
week 8 and week 16
Reported as:
Median · ng/mL
Change in D-dimer
ng/mLSevelamer Carbonate
Change in D-dimer-17.15 (-66.00 to 25.80)
SecondaryChange in Tissue Factor

Change in levels of coagulation biomarker tissue factor from baseline to week 4, where baseline value is the average of pre-entry and entry

Time frame:
baseline and week 4
Reported as:
Median · pg/mL
Change in Tissue Factor
pg/mLSevelamer Carbonate
Change in Tissue Factor-2.47 (-6.03 to 0.15)
SecondaryChange in Tissue Factor

Change in levels of coagulation biomarker tissue factor from baseline to week 8, where baseline value is the average of pre-entry and entry

Time frame:
baseline and week 8
Reported as:
Median · pg/mL
Change in Tissue Factor
pg/mLSevelamer Carbonate
Change in Tissue Factor-2 (-6.7 to -0.1)
SecondaryChange in Tissue Factor

Change in levels of coagulation biomarker tissue factor from week 8 to week 16

Time frame:
week 8 and week 16
Reported as:
Median · pg/mL
Change in Tissue Factor
pg/mLSevelamer Carbonate
Change in Tissue Factor3.8 (0 to 8)
SecondaryChange in Total Cholesterol

Change in total cholesterol from baseline to week 8, where baseline value is the average of pre-entry and entry

Time frame:
baseline and week 8
Reported as:
Median · mg/dL
Change in Total Cholesterol
mg/dLSevelamer Carbonate
Change in Total Cholesterol-12.5 (-28.50 to 5.50)
SecondaryChange in Total Cholesterol

Change in total cholesterol from week 8 to week 16

Time frame:
week 8 and week 16
Reported as:
Median · mg/dL
Change in Total Cholesterol
mg/dLSevelamer Carbonate
Change in Total Cholesterol9 (-4 to 25)
SecondaryChange in LDL Cholesterol

Change in fasting LDL cholesterol from baseline to week 8, where baseline value is the average of pre-entry and entry

Time frame:
baseline and week 8
Reported as:
Median · mg/dL
Change in LDL Cholesterol
mg/dLSevelamer Carbonate
Change in LDL Cholesterol-18.25 (-32.20 to 1.50)
SecondaryChange in LDL Cholesterol

Change in fasting LDL cholesterol from week 8 to week 16

Time frame:
week 8 and week 16
Reported as:
Median · mg/dL
Change in LDL Cholesterol
mg/dLSevelamer Carbonate
Change in LDL Cholesterol14.20 (-0.50 to 32.5)
SecondaryChange in HDL Cholesterol

Change in fasting HDL cholesterol from baseline to week 8, where baseline value is the average of pre-entry and entry

Time frame:
baseline and week 8
Reported as:
Median · mg/dL
Change in HDL Cholesterol
mg/dLSevelamer Carbonate
Change in HDL Cholesterol0.50 (-5 to 4)
SecondaryChange in HDL Cholesterol

Change in fasting HDL cholesterol from week 8 to week 16

Time frame:
from week 8 to week 16
Reported as:
Median · mg/dL
Change in HDL Cholesterol
mg/dLSevelamer Carbonate
Change in HDL Cholesterol1 (-3 to 5)
SecondaryChange in Non-HDL Cholesterol

Change in non-HDL cholesterol from baseline to week 8, where baseline value is the average of pre-entry and entry

Time frame:
baseline and week 8
Reported as:
Median · mg/dL
Change in Non-HDL Cholesterol
mg/dLSevelamer Carbonate
Change in Non-HDL Cholesterol-12 (-25 to 2)
SecondaryChange in Non-HDL Cholesterol

Change in non-HDL cholesterol from week 8 to week 16

Time frame:
week 8 and week 16
Reported as:
Median · mg/dL
Change in Non-HDL Cholesterol
mg/dLSevelamer Carbonate
Change in Non-HDL Cholesterol4 (-2 to 24)
SecondaryChange in Fasting Glucose

Change in fasting glucose from baseline to week 8, where baseline value is the average of pre-entry and entry

Time frame:
baseline and week 8
Reported as:
Median · mg/dL
Change in Fasting Glucose
mg/dLSevelamer Carbonate
Change in Fasting Glucose-2 (-12.75 to 2.92)
SecondaryChange in Fasting Glucose

Change in fasting glucose from week 8 to week 16

Time frame:
week 8 and week 16
Reported as:
Median · mg/dL
Change in Fasting Glucose
mg/dLSevelamer Carbonate
Change in Fasting Glucose3.5 (-3 to 15)
SecondaryPrimary Adverse Events

Number of subjects experiencing primary adverse events, defined as all reported Grade ≥ 2 signs and symptoms, Grade ≥ 2 laboratory abnormalities and other serious adverse events (SAEs)

Time frame:
baseline and week 16
Reported as:
Number · participants
Primary Adverse Events
participantsSevelamer Carbonate
Primary Adverse Events28

Adverse events

Collected over AEs reported from study enrollment until study completion at week 16. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sevelamer Carbonate—2/40 (5%)32/40 (80%)
Most frequent serious events
Most frequent serious events
EventSevelamer Carbonate
CellulitisInfections and infestations1/40
Joint injuryInjury, poisoning and procedural complications1/40
Most frequent other events
Showing 10 of 15
Most frequent other events
EventSevelamer Carbonate
Blood cholesterol increasedInvestigations11/40
Blood phosphorus decreasedInvestigations10/40
Blood bicarbonate decreasedInvestigations9/40
Blood glucose increasedInvestigations9/40
Blood calcium decreasedInvestigations8/40
Low density lipoprotein increasedInvestigations6/40
Blood glucose decreasedInvestigations5/40
Blood sodium decreasedInvestigations3/40
ConjunctivitisEye disorders2/40
Abdominal painGastrointestinal disorders2/40

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Sevelamer Carbonate
<=18 years0
Between 18 and 65 years39
>=65 years1
Age, Continuous
Age, Continuous(years)Sevelamer Carbonate
Median44 (34 to 51)
Sex: Female, Male
Sex: Female, Male(Participants)Sevelamer Carbonate
Female11
Male29
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Sevelamer Carbonate
White non-Hispanic10
Black Non-Hispanic24
Hispanic (regardless of Race)6
Region of Enrollment
Region of Enrollment(participants)Sevelamer Carbonate
United States40
Log10 HIV-1 RNA
Log10 HIV-1 RNA(copies/mL)Sevelamer Carbonate
Median3.58 (2.94 to 4.17)
CD4 count
CD4 count(cells/mm^3)Sevelamer Carbonate
Median580 (494 to 716)
08

Study locations

15 sites
  • Alabama Therapeutics CRS (5801)
    Birmingham, Alabama 35294, United States
  • UCLA CARE Center CRS (601)
    Los Angeles, California 90095, United States
  • Ucsf Aids Crs (801)
    San Francisco, California 94110, United States
  • Harbor-UCLA Med. Ctr. CRS (603)
    Torrance, California 90502, United States
  • University of Colorado Hospital CRS (6101)
    Aurora, Colorado 80045, United States
  • Univ. of Miami AIDS CRS (901)
    Miami, Florida 33136, United States
  • Northwestern University CRS (2701)
    Chicago, Illinois 60611, United States
  • Massachusetts General Hospital ACTG CRS (101)
    Boston, Massachusetts 02114, United States
  • Washington University CRS (2101)
    Saint Louis, Missouri 63110, United States
  • AIDS Care CRS (1108)
    Rochester, New York 14642, United States
  • Univ. of Rochester ACTG CRS (1101)
    Rochester, New York 14642, United States
  • Univ. of Cincinnati CRS (2401)
    Cincinnati, Ohio 45267, United States
  • Case CRS (2501)
    Cleveland, Ohio 44106, United States
  • Metro Health CRS (2503)
    Cleveland, Ohio 44109, United States
  • Hosp. of the Univ. of Pennsylvania CRS (6201)
    Philadelphia, Pennsylvania 19104, United States
09

References and documents

Publications

  • Sandler NG, Zhang X, Bosch RJ, Funderburg NT, Choi AI, Robinson JK, Fine DM, Coombs RW, Jacobson JM, Landay AL, Douek DC, Tressler R, Read SW, Wilson CC, Deeks SG, Lederman MM, Gandhi RT; AIDS Clinical Trials Group A5296 Team. Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection. J Infect Dis. 2014 Nov 15;210(10):1549-54. doi: 10.1093/infdis/jiu305. Epub 2014 May 26. PubMed 24864123 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Sep 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 29, 2012
First posted
Mar 5, 2012
Start
Nov 2011
Primary completionActual
Sep 2012
CompletionActual
Nov 2012
Results first posted
Nov 25, 2013
Last update
Oct 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01543958
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Responsible party
Sponsor
First posted
Mar 5, 2012
Start date
Nov 2011
Primary completion
Sep 2012
Completion
Nov 2012
Results posted
Nov 25, 2013
Last update
Oct 11, 2018

Study contacts

Rajesh Gandhi, MD
study chair · Massachusetts General Hospital ACTG CRS
Netanya Sandler, MD
study chair · National Institutes of Health (NIH)

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sevelamer

Start the discussion